Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial.

Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or III symptoms and a left ventricular ejection fraction less than or equal to 40% were enrolled in the study and were randomized to receive either placebo, 50mg, 150mg or 300mg of trientine-HCL twice daily.

Results suggest a 20% reduction in NTproBNP at 4 and 8 weeks and improvement in 6-minute walk distance and KCCQ-OSS in the 300mg cohort.

Recorded on-site at HFA 2023, Prague.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter:

Чтобы скачать видео "HFA 23: TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction" передвинте ползунок вправо